Lilly's EBGLYSS (Lebrikizumab-Lbkz) Is The First And Only Selective Il-13 Inhibitor To Deliver Positive Phase 3 Outcomes In Patients Aged Six Months To 18 Years With Moderate-To-Severe Atopic De
Reuters03-16 19:39
March 16 (Reuters) - Eli Lilly and Co :: *LILLY'S EBGLYSS (LEBRIKIZUMAB-LBKZ) IS THE FIRST AND ONLY SELECTIVE IL-13 INHIBITOR TO DELIVER POSITIVE PHASE 3 OUTCOMES IN PATIENTS AGED SIX MONTHS TO 18 YEARS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS *ELI LILLY - ANNOUNCES POSITIVE PHASE 3 RESULTS FOR EBGLYSS IN PEDIATRIC ATOPIC DERMATITIS *ELI LILLY - IN PHASE 3, 63% ACHIEVED EASI-75 AND 44% ACHIEVED IGA 0,1 AT WEEK 16 *ELI LILLY - EBGLYSS SAFETY PROFILE CONSISTENT WITH PRIOR STUDIES; NO INJECTION SITE PAIN REPORTED *ELI LILLY - TO SUBMIT DATA FOR POTENTIAL LABEL UPDATE TO U.S. AND GLOBAL REGULATORS
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments